A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
← catalyst calendarSponsored by Palvella Therapeutics, Inc. (industry) · PVLA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
45estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-15 | actual | When the study began enrolling |
| Primary completion | Oct 2023 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2023 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-12-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pachyonychia Congenita
Intervention
- Drug: PTX-022
Primary outcome
what the primary-completion date above is the date OFTreatment emergent adverse events
measured 6 months
Permalink · PVLA's whole pipeline · Catalyst calendar · Every registered study · What changed